PHE 377

Drug Profile

PHE 377

Alternative Names: PHE377; V-377

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator PharmEste
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 22 Apr 2016 Discontinued - Phase-I for Neuropathic pain in Switzerland & United Kingdom (PO)
  • 20 May 2011 Phase-I clinical trials in Neuropathic pain in United Kingdom (PO)
  • 18 Jul 2009 Phase-I clinical trials in Neuropathic pain in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top